|Day Low/High||247.78 / 249.75|
|52 Wk Low/High||195.50 / 340.34|
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
- Famed actress launches charitable partnership with Guide Dogs for the Blind and discusses her experience and treatment with RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% -
-- Patients currently treated with donepezil hydrochloride 10 mg can now start therapy directly with once daily NAMZARIC --
Cramer is a fan of Danaher and says to stick with CBRL Group.
Monday's headlines predicted a gloomy earnings season, Cramer says. What were they thinking?
Stocks kept climbing this week as earnings season got into high gear. We cut one name from the portfolio and rerated a few holdings.
The Israeli pharmaceutical company ought to achieve good terms as fixed-income investors flock to corporate bonds.
The drug maker is a compelling buy and has 50% upside potential over the next 18 to 24 months.
At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.
The House Republicans' tax reform plan is a pretty good deal according to one analysis, especially for American corporations.
Continue a repair trade in AGN with a ratio call spread on top of stock already owned.
Here's a technical look at how to trade some of the most active stocks on the market right now.
A look at how we are evaluating today’s market action.
Sequoia Fund has sold its position in Valeant Pharmaceuticals and has added four new positions.
The company once held a 30% stake in Valeant, now owns no Valeant shares.
Endo Pharmaceuticals is most under pressure, analysts say.
Cramer says there are several reasons why the market has risen since the Brexit vote.
They need to do something that makes them stand out as stocks you want to own, not avoid.
We adjusted our holdings this week in four portfolio names, adding to Comcast and Visa but trimming Costco and Walgreens.
What do the charts say for these four stocks included on Goldman Sachs' Conviction Buy List?
Goldman Sachs expects "rising uncertainty" in the second half of 2016 and suggests that investors stick to stocks within defensive sectors including consumer, health care and telecom services.